


Figure 1

A



B





Figure 1





Figure 2

A



B




Figure 2

C





Figure 3

A



B




Figure 4




Figure 5A







Figure 5B



- Group 01: Vehicle QD / BIW
- ◇ Group 03: Compound I 35mg/kg QD
- △ Group 04: Tafasitamab 10mg/kg BIW
- ◆ Group 08: Compound I 35mg/kg QD + Tafasitamab 10mg/kg BIW
- ▼ Compound I application p.o.
- ▼ Tafasitamab treatment i.v.



- Group 01: Vehicle QD / BIW
- Group 02: Compound I 50mg/kg QD
- △ Group 04: Tafasitamab 10mg/kg BIW
- Group 06: Compound I 50mg/kg QD + Tafasitamab 10mg/kg BIW
- ▼ Compound I application p.o.
- ▼ Tafasitamab treatment i.v.

Figure 6

